---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004063"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:16:26.147492+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics receives SEC Wells Notice; CEO placed on paid administrative leave

## Summary
- SEC staff preliminarily recommends enforcement action over 2022 disclosures on tebipenem HBr commercialization.
- CEO Satyavrat Shukla agrees to paid administrative leave; CFO Esther Rajavelu appointed interim CEO.
- Director Frank Thomas replaces Dr. Ankit Mahadevia as Chairman of the Board.
- Preliminary cash and equivalents of $52.9M as of Dec 31, 2024; runway into mid-2026.
- Phase 3 PIVOT-PO trial enrollment exceeds 60%; on track for full enrollment in 2H 2025.

## SEC filing metadata
- accession: 0001193125-25-004063
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312525004063/0001193125-25-004063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312525004063/d820907d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004063
- JSON: https://secwatch.observer/filing/0001193125-25-004063.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.